TDO2 inhibition counters Benzo[a]pyrene-induced immune evasion and suppresses tumorigenesis in lung adenocarcinoma
This study highlights the key mechanisms behind BaP-induced immune evasion in LUAD, particularly through the TDO2/AhR axis. It reveals how TDO2 inhibitors can counteract immune checkpoint activation and boost anti-tumor immunity, suggesting new paths for targeted lung cancer immunotherapy. The findings significantly improve our understanding of immune evasion in LUAD and underscore the therapeutic promise of TDO2 inhibition.
Authors
- Jong-Jin Kim (ORCID: https://orcid.org/0000-0001-5234-7856)
- Mücahit Varlı (ORCID: https://orcid.org/0000-0001-6175-4015)
- Sultan Pulat (ORCID: https://orcid.org/0000-0001-9871-8296)
- İsa Taş (ORCID: https://orcid.org/0000-0001-5306-8584)
- Hyun Bo Sim (ORCID: https://orcid.org/0009-0000-6430-9814)
- Hangun Kim (ORCID: https://orcid.org/0000-0001-5889-8907)
Institutions
- Sunchon National University (KR)
Publication Details
- Journal
- Cancer & Metabolism
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s40170-024-00365-z
- Citations
- 6
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea